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Abstract
Introduction: Classic anti-nucleolar antibodies anti-Th/To and U3 ribonucleoprotein (-U3RNP) can help in the
diagnosis, prediction of organ involvement and prognosis in systemic sclerosis (SSc); however, no validated
commercial assay is available. We aimed at establishing a novel quantitative real time PCR (qPCR) method to
detect these antibodies.
Methods: Standard immunoprecipitation (IP) was performed using K562 cell extract and RNA components were
extracted. cDNA was reverse transcribed from RNA components and Th RNA and U3 RNA were detected by qPCR
using custom primers. Cycle threshold (Ct) values were compared in a titration experiment to determine the assay
efficacy. The new assay was evaluated by testing 22 anti-Th/To and 12 anti-U3RNP positive samples in addition to
88 controls, and the results were compared with IP as a gold standard.
Results: By testing serial 1:8 dilutions of cell lysate as the substrate in the IP step, RNA extracted after IP, and its
derived cDNA, linear dose response curves were noted for both anti-Th/To and -U3RNP. With every dilution, Ct
values changed approximately three as expected, reflecting the eight-fold difference of cDNA. The Ct difference
between positive and negative samples was 8 to 13, which was similar throughout the dilutions. In the specificity
analysis, the Ct values of positive samples were clearly different from the negative groups and the results by qPCR
had a near perfect correlation with IP.
Conclusions: Our new method readily detects these two clinically important antibodies in SSc. Making tests for
anti-Th/To and -U3RNP antibodies widely available to clinicians should be helpful in the diagnosis and follow-up of
SSc patients.
Introduction
Scleroderma (Systemic Sclerosis, SSc) is a systemic auto-
immune disease characterized by fibrosis, vascular
changes, and the production of autoantibodies. The
most common antibodies associated with SSc are anti-
centromere (ACA), -topoisomerase I (topo I) and -RNA
polymerase III (RNAPIII) antibodies, approximately 20%
each [1-5]. Anti-topo I and ACA have been used for
about 30 years for diagnostic purposes, while anti-RNA-
PIII ELISA has been added to routine screening only
recently [6-8]. SSc patients can be classified into two
major subsets: limited (lcSSc) and diffuse (dcSSc)
cutaneous variants. The dcSSc is frequently associated
with anti-topo I, -RNAPIII, or -U3RNP, while lcSSc is
associated with ACA and anti-Th/To antibodies [1,9].
These autoantibodies are fairly specific for SSc and can
be detected even before diagnosis. They are associated
with unique clinical features and are useful in predicting
clinical manifestations of SSc [1,10-12].
Anti-Th/To and -U3RNP are anti-nucleolar antibodies
that have been known for more than 25 years. Despite
their clinical importance, these SSc autoantibodies have
not been utilized clinically because of the unavailability
of antibody testing [7,13]. Urea-polyacrylamide gel elec-
trophoresis (PAGE) analysis of the RNA components in
immunoprecipitates, either by silver staining or by using
32P-labeling of cells, is the standard method, but it is
performed only in a small number of research
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laboratories. No commercial widely-available validated
immunoassay kit has been produced so far [14]. The
aim of our study is to establish a new method to detect
anti-Th/To and -U3RNP antibodies based on quantita-
tive PCR (qPCR) detection of the RNA components of
the ribonucleoprotein autoantigens.
Materials and methods
Immunoprecipitation and quantitative PCR
Immunoprecipitation (IP) was performed using K562
cell lysate and associated RNA was extracted using phe-
nol/chloroform/isoamyl alcohol (25:24:1) as described
[13,15]. RNA pellets were resuspended in 30 µl RNA-
grade water. cDNA was obtained from each RNA sam-
ple (10 µl) by reverse transcription (RT) using RT Mas-
ter Mix (High Capacity cDNA RT kit, Applied
Biosystems Inc., ABI, Foster City, CA, USA). The ther-
mal cycler for the RT setting was: 10 minutes at 25°C,
120 minutes at 37°C, 5 seconds at 85°C. Quantitative
PCR (qPCR) was performed using the TaqMan Fast
Universal PCR Master Mix (ABI). For Th RNA (7-2
RNA, RMRP) detection, ‘Hs03298751_s1’ primer by ABI
was used, while the primer for U3 RNA (SNORD3A,
Integrated DNA Technologies, Coralville, IA, USA) has
the following sequence: Probe 5’-/56-FAM/CCAAG-
CAAC/ZEN/GCCAGAAAGCCG/3IABkFQ/-3’; Primer 1
(FOR.) 5’-TGTAGAGCACCGAAAACCAC-3’; Primer 2
(REV.) 5’-TCCCTCTCACTCCCCAATAC-3’. qPCR was
performed in duplicate using the StepOne cycler (ABI)
for 40 cycles, and results were evaluated by cycle thresh-
old (Ct) values.
In some experiments, La-depleted cell extract was also
used to examine the effects of La depletion in a limited
number of samples (n = 24). An extract from 25 × 106
K562 cells was absorbed with 0.5 ml of anti-La immu-
noglobulin G-cyanogen bromide (IgG-CNBr)-activated
Sepharose 4B beads to deplete La [16].
Serum samples
The protocol of this study was approved by the Institu-
tional Review Board (IRB). This study meets and is in
compliance with all ethical standards in medicine and
informed consent was obtained from all patients accord-
ing to the Declaration of Helsinki. For the titration
experiment, one each of anti-Th/To, -U3RNP and nor-
mal human serum (NHS) was tested, with serial eight-
fold dilutions (from 1 to 1:4096) of cell lysate as sub-
strate in the IP step, RNA extracted after IP, and its
derived cDNA. To validate the new assay, 22 anti-Th/
To, 12 anti-U3RNP-positive samples, 58 SSc sera nega-
tive for anti-Th/To and -U3RNP antibodies (20 anti-
Topo I, 18 anti-RNAPIII, 15 ACA, 5 anti-PM-Scl), 12
anti-La/SSB, 3 anti-trimethylguanosine (TMG) [17], and
15 NHS, were analyzed. The specificity of these sera was
confirmed by IP and urea-PAGE analysis as described
[13]. Our data are representative of two or more inde-
pendent experiments. PCR was analyzed in duplicate
and immunoprecipitation was also tested in duplicate in
some experiments. The typical reproducibility was very
high showing a difference within one Ct value. In the
new assay described here, no housekeeping gene mRNA
would be present constantly, which is different from the
standard qPCR used to examine the levels of mRNA for
the gene of interest in total RNA or total mRNA. Never-
theless, the level of 18S RNA was also examined as a
potential internal control for nonspecific binding (data
not shown), but the results showed variation in its levels
so that it was not considered suitable as an internal con-
trol in our assay.
Statistical analysis
Data between groups were compared by Kruskal-Wallis
and Dunn’s multiple comparison tests using Prism 5.0
for Macintosh (GraphPad Software, Inc). The same pro-
gram was applied to obtain the receiver operating char-
acteristic (ROC) curves, comparing the anti-Th/To or
-U3RNP positive group versus the negative group to
determine the cut-off. Statistical significance was
accepted at P <0.05.
Results
Autoantibody detection using qPCR for the RNA
component of the ribonucleoprotein autoantigen
complex
The sensitivity and linearity of the assay was evaluated
for the detection of the Th and U3 RNA components,
using serial 1:8 dilutions (1-1:4096) of cell lysate, RNA
purified after IP (both started from extracts of 107 cells
per sample, but data shown are based on the use of 10
out of 30 µl of RNA, equivalent to 3.3 × 106 cells) and
cDNA obtained after RT (the equivalent of cDNA made
from RNA derived from 3.3 × 106 cells) (Figure 1). Ct
values for the titration using serially diluted cell lysate
were 8.3 (extract from 107 cells, equivalent to undiluted
or ‘1’ in Figure 1A) to 22.7 (extract from 2.4 × 103 cells,
corresponding to 1:4096 in Figure 1A) for Th RNA and
13.4 to 28.9 for U3 RNA (not shown), using the proto-
type sera. Linear dose response curves were noted for
cell lysate, RNA, and cDNA dilutions, and the difference
between positive samples and NHS was clear even at
1:4096 dilution, which corresponded to a cell extract
from 2.4 × 103 K562 cells (Figure 1A). Ct values chan-
ged by approximately three for every 1:8 dilution,
reflecting the eight-fold difference and the high effi-
ciency of the qRT-PCR as expected (Figure 1A). Similar
titration of RNA and cDNA, shown in Figure 1B and
1D, demonstrated the same linear relationship in each
step of the qRT-PCR. IP using the standard 8 µl of
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human serum versus 1 µl was also compared in the
titration experiment, to examine the effects on the Ct
values. The difference in Ct values was approximately
three, further demonstrating the high sensitivity of the
new method also with 1 µl of serum.
The sensitivity of detection of Th or U3 RNA by the
qPCR method was compared with that of the standard
urea-PAGE-silver staining method by testing the same
amount of serially diluted Th RNA (Figure 1B versus C)
or U3 RNA (not shown). When using serial dilutions of
RNA, the qPCR assay clearly detected a signal at the
highest dilution of 1:4096 (Figure 1B) whereas Th RNA
was barely visible only up to 1:16 dilution by silver stain-
ing (Figure 1C). Thus, qPCR was at least 256-fold more
sensitive than silver staining. For U3 RNA detection,
qPCR was clearly positive at a dilution of 1:4096, simi-
larly to 7-2 RNA, whereas U3 RNA was detected only up
to a 1:8 dilution by silver staining (data not shown), indi-
cating that the qPCR assay was at least 512-fold more
sensitive. Based on these data, cell extracts from one mil-
lion cells, which correspond to 1/10th the amount of cell
lysate normally used for IP, were used for screening of
sera for anti-Th/To, -U3RNP, and other antibodies.
Specificity of IP-qPCR assay applied to clinical samples
The mean Ct value was 19.81 (standard deviation (SD)
1.45) for anti-U3RNP and 15.27 (SD 0.73) for anti-Th/
To samples (Figure 2A, B). These values were clearly
separated from those of the control groups, with a dif-
ference of approximately eight Ct values for anti-
U3RNP and approximately 13 Ct values for anti-Th/To
(P <0.05) (Figure 2A, B). The Ct values of anti-TMG
sera were similar to those of anti-U3RNP positive sera
(Figure 2A). This was expected since anti-TMG antibo-
dies recognize the cap structure on U1-U5RNA, includ-
ing U3RNA [17]. Despite maintaining statistical
significance, the Ct difference between anti-Th and -La
samples was smaller than the Ct difference between
anti-Th and other negative controls (Figure 2C). This
could be explained based on the interaction and co-
immunoprecipitation of Th RNA by La antigens, as
shown previously [18]. For this reason, anti-La sera were
also tested in the IP-qPCR assay using La-depleted K562
cell lysate. Ct values increased by about two and became
comparable to other negative groups when La-depleted
cell lysate was used in place of whole cell lysate (data
not shown). This indicated that the low Ct values of
anti-La sera in the anti-Th qPCR assay were due to co-
IP of the Th RNA by the La complex, and not by coex-
isting anti-Th antibodies. When testing anti-U3RNP
samples, 5/12 anti-La positive samples had low Ct
values, which fell below the cut-off (Figure 2A). This
might be explained by the observation that La could
bind and stabilize precursors of the U3 small nucleolar
Figure 1 High sensitivity and linear detection of anti-Th/To antibodies in the IP-qPCR assay demonstrated by titration analyses. One
prototype anti-Th/To sample and NHS were analyzed, and Ct values plotted against serial dilution of cell lysate used as substrate for IP (A), RNA
extracted from IP (B), or the derived cDNA (D). Dilutions start with lysate from 107 K562 cells per sample. C. The sensitivity of our new IP-qPCR
method is compared with RNA dilution detected by silver staining, which allows the identification of the two RNA bands (8-2 RNA, 7-2 RNA)
only up to 1:16 dilution. Ct, cycle threshold; IP-qPCR, immunoprecipitation-quantitative polymerase chain reaction; NHS, normal human serum.
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RNA to prevent degradation [19]. Thus, U3RNA could
be weakly detected in the anti-La immunoprecipitate.
Considering IP with silver staining as the gold stan-
dard for the detection of anti-Th and -U3RNP antibo-
dies, the sensitivity by our new IP-qPCR method was
100% for both (Table 1). Assay specificity for anti-Th
and -U3RNP in SSc patients was 100% and 98.9%,
respectively (Table 1). For anti-U3RNP detection, one
anti-Th/To serum was repeatedly positive for an
unknown reason.
Discussion
The importance of the development of a convenient
assay for anti-Th/To and -U3RNP antibodies cannot be
underestimated because these two classic anti-nucleolar
autoantibodies are associated with particular SSc var-
iants and clinical features [1]. In fact, anti-Th/To anti-
bodies are frequently detected in lcSSc patients with
pericarditis and mild lung involvement [13,20], while
anti-U3RNP antibodies are associated with severe pul-
monary, renal and muscular disease, mainly in African-
American dcSSc patients [1,21]. Thus, the aim of our
study was to establish a new method that can be used
widely and easily to detect anti-Th/To and -U3RNP
antibodies to replace complicated RNA analysis by gel
electrophoresis.
Our results clearly show that qPCR is highly efficient
and reliable to detect the RNA components of the SSc
nucleolar autoantigens, when data are compared with
the gold standard IP. Advantages of this new method
include easy application without technically demanding
RNA analysis by urea-PAGE and without the use of
toxic chemicals (for example, acrylamide, silver staining)
or 32P radioisotopes. The results obtained by our IP-
qPCR assay are consistent and reproducible, and are
Figure 2 Specific detection of anti-Th/To and U3RNP antibodies by IP-qPCR assay. A, B. Sera with antibodies to Th/To (n = 22), U3RNP (n
= 12), TMG (n = 3), La (n = 12), topo I (n = 20), RNAPIII (n = 18), ACA (n = 15), PM-Scl (n = 5), and normal human sera (NHS, n= 15) were
tested by the IP-qPCR method. Data points and median bar are representative of at least two independent experiments. P < 0.05 by Kruskal-
Wallis and Dunn’s multiple comparison tests was present among all the groups, with the exception of the anti-U3RNP/anti-TMG groups (P = ns).
The cut-off was determined by ROC curve and positive range is shown as shaded areas. ACA, anti-centromere antibodies; IP-qPCR,
immunoprecipitation-quantitative polymerase chain reaction; NHS, normal human serum; RNAPIII, RNA polymerase III; ROC curve, receiver
operating characteristic curve; TMG, trimethylguanosine; topo I, topoisomerase I.
Table 1 Sensitivity and specificity of our new IP-qPCR
method.
Autoantibody specificitya n Anti-Th/To
by IP-qPCR
Anti-U3RNP
by IP-qPCR
Scleroderma
Th/To 22 100% 4.5% (1/22)
U3RNP 12 0% 100%
Topo I 20 0% 0%
RNAPIII 18 0% 0%
ACA 15 0% 0%
PM-Scl 5 0% 0%
Others
TMG 3 0% 100%
La 12 0% 42% (5/12)
NHS 15 0% 0%
Results show the high sensitivity and specificity of the new assay, for the
detection of anti-Th/To and -U3RNP antibodies, compared with silver staining
as gold standard. aAntibody specificity validated by IP, urea-PAGE, and silver
staining. ACA, anti-centromere antibodies; IP, immunoprecipitation; NHS,
normal human serum; RNAPIII, RNA polymerase III; TMG, trimethylguanosine;
topo I, topoisomerase I.
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expressed as semi-quantitative data, while the silver
staining gel only detects the presence or absence of spe-
cific bands. The high sensitivity of our new method is
demonstrated by requiring cell extract from only one
million cells and 1 µl of serum to obtain a signal that is
at least 128- to 512-fold more sensitive than standard
IP-silver staining method. Another important advantage,
when considering its use in a large laboratory setting, is
the high number of samples that the new assay can han-
dle at a time. In fact, a 96-well plate can be used for
qPCR, while only 10 to 16 samples can be tested in a
standard gel for RNA analysis by urea-PAGE.
A minor limitation of the IP-qPCR assay is the lack of
information on other RNAs immunoprecipitated by the
same serum sample. Examples are co-IP of 7-2 and 8-2
RNA by La antigen [18,22], and U3 RNA by rare auto-
immune sera that recognize the TMG cap structure of
U1-U5RNA [17]. In practice, it will be reasonable to
apply this qPCR method for anti-Th/To and U3RNP
antibodies only to SSc patients who are negative for
anti-topo I, RNAPIII, and ACA, since the coexistence of
multiple SSc autoantibodies is uncommon [1]. Also,
nucleolar immunofluorescence staining in antinuclear
antibody (ANA) screening will be helpful to decide
which patients should be tested by this IP-qPCR
method, since the majority of anti-Th/To- and U3RNP-
positive patients show clear nucleolar staining [13,23], in
contrast to anti-RNAPI/III sera which often do not
show a nucleolar pattern [7,9]. It should be noted that
the specificity of the IP-qPCR assay is nearly 100% in
SSc samples and that non-SSc sera that are expected to
be, or potentially are, false positives (such as anti-La,
anti-TMG) were included in the study to clarify the
potential limitations of the assay. The SSc sera we tested
were not randomly selected, however, the proportion of
each specificity is not far from a randomly selected SSc
cohort, and it should give us a reasonable idea of the
specificity of the assay in general SSc patients. Thus, the
positive results obtained by the new IP-qPCR assay in
the presence of rare antibodies in SSc, such as anti-La
and anti-TMG, do not represent a clinically significant
problem.
The new method can be readily applied to detect
other autoantibodies, such as autoantibodies to aminoa-
cyl-tRNA synthetases and signal recognition particle
(SRP) in polymyositis/dermatomyositis patients, just by
using appropriate specific primers for the RNA species
of interest. With the IP-qPCR method, each tRNA spe-
cificity can be readily defined without the complicated
aminoacylation assay [24]. Although clinical manifesta-
tions of many anti-synthetase antibodies appear similar
and they are known as the ‘anti-synthetase syndrome’, it
is possible that fine specificity still has clinical signifi-
cance as there are some suggestions of different clinical
manifestations in patients with different anti-synthetase
antibodies [15,25,26].
Conclusions
We have established a new method to detect autoanti-
bodies to Th/To and U3RNP based on qPCR detection
of the RNA components of the autoantigens. High spe-
cificity and sensitivity compared with the gold standard
IP were confirmed. This new assay will be useful for
detection of autoantibodies to any RNA-protein com-
plex autoantigen and may allow clinical utilization of
several autoantibodies that have been mainly detected
by IP and not utilized widely in the past.
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